Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market

2020 Analysis and Review: MRSA Treatment Market by Indication - SSTI, Pneumonia, Bloodstream Infections, Surgical and Medical Infections for 2020-2030

  • 2020-06-15
  • REP-GB-10406
  • 63 Tables
  • 96 Figures
  • 345 pages
  • Format: PDF/PPT/Excel

An Incisive, In-depth Analysis on the Methicillin Resistant Staphylococcus Aureus Testing Market

This study offers a comprehensive, 360 degree analysis on the Methicillin Resistant Staphylococcus Aureus Testing market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Methicillin Resistant Staphylococcus Aureus Testing market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Outlook & Key Findings

  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment market to reach USD 3.66 Bn in 2020 (up by 2.37% over 2019)
  • Pharma industry moving toward a combination of genomic surveillance and laboratory testing to find new treatment options
  •  Bearish financial outlook for companies engaged in antibiotic research driving away investors 
  • Use of machine learning and AI to develop superior antibiotics likely to gain ground during 2020-2030          

Who is at Risk of MRSA Infection?

MRSA infection is highly contagious and can spread through person-to-person contact or a surface or object touched by MRSA-infected person.

If MRSA is contracted in nursing homes or hospitals, it is through contaminated hands, direct contact with the undressed wound, poorly sanitized surgical instruments, or contaminated linens. This hospital-acquired MRSA (HA-MRSA) could further cause pneumonia and blood infections. Outside of healthcare settings, the infection is known as community-acquired MRSA (CA-MRSA).

Those who undergo hemodialysis on regular basis are at the highest risk of contracting HA-MRSA. Further, those staying in nursing homes and the ones who had been hospitalized are also at risk.

On the other hand, CA-MRSA prevalence is higher among individuals involved in contact sports, the ones living in unhygienic conditions, and those working in day care centers.

Oral Antibiotics Remain the First Treatment Option for MRSA Infection Treatment

Oral antibiotics are administered to MRSA-infected patients as the first course of action. Vancomycin is one such antibiotic recommended by IDSA (Infectious Disease Society of America).

With increasing incidences of MRSA across the globe (with the U.S., Canada, Japan, and Indonesia having the highest rates as per the WHO), the demand for the above-mentioned oral antibiotic is likely to increase manifold, thereby boosting the MRSA treatment market.

Covid-19 Crisis Impact - Significant Rise in Secondary MRSA Infections to Catalyze the Market

The outbreak of Covid-19 has increased the risk of secondary infections. Covid-19 positive individuals are reported to be more vulnerable to MRSA infections.

According to Centers for Disease Control (CDC) 1 in 7 Covid-19 hospitalized patients have contracted secondary bacterial infections, and the infection has proven to be fatal in 50% of these patients.

These factors are likely to raise short-term demand for first-line antibiotic treatment against secondary MRSA infections in Covid-19 patients.

MRSA Treatment Market Moderately Consolidated with a Few Specialized Industry Players

The key players are on the “innovation” spree to consolidate their market share. Everyone – right from top tier innovator companies to small size developer companies are looking out for differentiators in this regard. The top-notch players are going for production of new antibiotics, acquisition, and exclusive product licensing to mitigate the entry of small and new companies. The other strategies followed are “exclusive distribution” and “development collaborations”.

Although advanced MRSA treatments have sprung up all over the globe, most of the leading manufacturers are U.S.-based.

Pfizer Inc. alone owns a significant share of the U.S. market, but the marketplace is rapidly becoming competitive owing to gains made by players such as Melinta Therapeutics, Inc. The company received FDA approval for Baxdela (delafloxacin) for extended indication in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria).

In January 2018, Cutis Pharma Inc., a US based specialty pharmaceutical company, obtained approval for its Firvanq (vancomycin hydrochloride) oral solution for gastrointestinal infection of MRSA.

Extensive Research to Combat MRSA Infection

Scientists at Boston University’s College of Engineering (Massachusetts) have found that a blue light LASER is capable of killing MRSA without causing any harm to healthy cells. This accidently discovered phenomenon is likely to encourage the government of the U.S. to pump in more funds for MRSA treatment from “non-biomedical” perspective. This would ask for more scientists to be on this task, thereby bolstering the market on the whole.

As per Emory School of Medicine’s Department of Dermatology and Emory University’s Center for the Study of Human Health, the triterpenoid acids present in the Brazilian peppertree’s (Schinus terebinthifolia’s) red berries help in destruction of MRSA. 

As per a study performed by researchers from “Madda Walabu University (Ethiopia), honey’s acidic nature (pH between 3.2 and 4.5) acts as a bactericide. In other words, honey combined with isolates of MRSA results in release of H2O2 (Hydrogen Peroxide). The compound is highly effective against staphylococcus bacteria. This successful experiment is likely to open doors for alternative medicines, and provide an impetus to the growth of the market.

Scientists at Marshall University School of Pharmacy have received a grant for 3 years from NIH (National Institutes of Health) for studying usage of disulfiram in treating MRSA infections.

Misdiagnosis and Poor Access to MRSA Treatment: Key Industry Challenges for MRSA Treatment Market

In many countries of South Asia, Latin America, and Middle East and Africa, basic healthcare system is poorly established and weak to provide advanced treatments such as MRSA treatment. Incorrect diagnosis is rampant in many developing countries, which creates the potential for serious consequences.

There is every likelihood of MRSA-causing infections striking a similarity with the ones caused by the other non-resistant bacteria. This could also result in misdiagnosis and the patients many end up being administered an antibiotic not meant for treating MRSA.

It’s critical to get precise diagnosis as appropriate treatment does lower risk of infection becoming invasive. Some of the commonly used antibiotics for MRSA include trimethoprim-sulfamethoxazole (Bactrim), doxycycline (Doryx), and clindamycin (Cleocin).

AI and Machine Learning to Table Superior Antibiotics

Researchers at MIT, of late, did discover a novel antibiotic using ML (Machine Learning) algorithms known as “Halicin”. It is reported to have successfully eliminate several bacterial strains; inclusive of the ones on WHO’s hitlist. Though this was the first of its kind; efforts are being made to devise more such antibiotics.

MRSA Treatment: Region-wise Analysis

North America continues to be the most lucrative market for MRSA treatment. The US MRSA treatment market has grown steadily over the last five years, and is set to grow at over 3.8% in 2020.

University of Melbourne’s researchers state that “Teixobactin” responds positively against MRSA. This will surge the MRSA treatment market all over Australia and the other countries in Asia-Pacific.

Besides, Asia-Pacific is amongst the regions having the highest number of MRSA-infected population. Multilocus Sequence type (ST) 239 and ST5 – two pandemic HA-MRSA clones have spread across the region.

CA-MRSA’s molecular epidemiology gets identified by “clonal heterogeneity”; analogous to Europe. Another area to look into is “MRSA strains in livestock” in both these regions. Studies are being conducted to mitigate infections from livestock.

In North America, Europe, South Asia, and East Asia, share of SSTIs (Skin and Soft Tissue Infections) is the highest. Pneumonia and bloodstream infections follow suit. Surgical and medical infections are the other widely prevalent infections.

MRSA Treatment Market: Competitive Landscape

The MRSA treatment market is witnessing the entry of new players, albeit at a local or regional level. With an estimated 20+ MRSA treatment players, clinical developments, new product launches, have become key avenues for being a class apart.

As of now, the players are concentrating on dosage in topical form. As such, clinical trials are being conducted to devise unique drug molecules. Besides, “research and development” is of prime focus over here. Just like the Brazilian peppertree; research is “ON” regarding positive outcomes from the other plants.

Some of the key players in the MRSA treatment market are:

Americas

  • Pfizer, Inc.
  • Allergan Plc.
  • Johnsons & Johnson
  • Merck & Co., Inc.
  • Baxter Healthcare Corporation
  • Bausch Health Companies Inc.
  • Cumberland Pharmaceuticals Inc.
  • Mylan N.V.
  • Melinta Therapeutics, Inc.
  • Akron Pharma Inc.
  • Amneal Pharmaceuticals, Inc.
  • Herbal Intervention, LLC
  • Bio-Germ Protection LLC

Europe

  • Novartis AG
  • Debiopharm International SA
  • Fresenius Kabi LLC

Asia Pacific

  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Mayne Pharma Group Limited.

*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report

MRSA Treatment: The Way Forward

The long-term outlook on MRSA treatment market remains upbeat, with FMI’s analysis estimating revenue to grow at over 4% consistently. Global outbreak of Covid-19 has created a short-term demand of the MRSA treatment therapeutics in the pneumonia indication segment across the global market. However, skin and soft tissue infections (SSTIs) is also expected to gain traction in the long-term market opportunities.

MRSA treatment market players will need to move beyond their conventional approaches of MRSA antibiotic development to target wider unmet needs of patients such as non-invasive and invasive MRSA infections. Portfolio strengthening and wider indications of MRSA treatment therapeutics are needed to be focused by the leading industry players. To increase sales in cost-sensitive, yet lucrative markets, collaborative approach with local government and healthcare authorities are needed for introducing a new set of patients; and, not to forget, keeping pace with technology – say Machine Learning and Artificial Intelligence.

Methicillin-resistant Staphylococcus aureus (MRSA) Treatment Market: Global Industry Analysis 2015-2019 & Opportunity Assessment 2020-2030  

A recent market study published by Future Market Insights on the MRSA treatment market includes global industry analysis for 2015-2019 & opportunity assessment for 2020-2030, and delivers a comprehensive assessment of the most important market dynamics and Covid-19 crisis impact analysis. After conducting a thorough research on the historical as well as current growth parameters of the market, the growth prospects of the market are obtained with maximum precision.

MRSA Treatment Market: Segmentation

The global MRSA treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug Class

  • Glycopeptides
    • Vancomycin
  • Lipopeptides
    • Daptomycin
  • Oxazolidinones
    • Linezolid
  • Glycylcycline
    • Tigecycline
  • Streptogramins
    • Quinupristin
    • Dalfopristin
  • Lincomycin
    • Clindamycin
  • Tetracycline
    • Doxycycline
    • Minocycline
  • Lipoglycopeptides
    • Dalbavancin
    • Telavancin
    • Oritavancin
  • Antiseptics
    • Chlorhexidine
    • Cetylpyridinium Chloride
    • Hydrogen Peroxide
    • Phenols
  • Naturals/Herbals
  • Others

Route of Administration

  • Intravenous
  • Oral
  • Topical
  • Nasal
  • Cutaneous
  • Intramuscular

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drugstores
  • Online Pharmacies

Indication

  • Skin and Soft Tissue Infections (SSTIs)
  • Pneumonia
  • Bloodstream Infections
  • Surgical and Medical Infections
  • Others

Types of MRSA

  • Healthcare Acquired MRSA
  • Community Acquired MRSA
  • Hospital Acquired MRSA

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Report Chapters

Chapter 01 – Executive Summary

The report initiates with the executive summary of the MRSA treatment market, which includes a summary of key findings and statistics of the market. It also includes supply-side and demand-side trends pertaining to the MRSA treatment market.

Chapter 02 – Market Overview

Readers can find the definition and a detailed segmentation of the MRSA treatment market in this chapter, which will help them understand the basic information about the MRSA treatment market. Along with this, comprehensive information pertaining to drug class of MRSA treatment products and their features are provided in this section. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the MRSA treatment market report.

Chapter 03 – Key Market Trends

MRSA treatment market report provides the key market trends that are expected to significantly impact market growth during the forecast period. Detailed industry trends are provided in this section.

Chapter 04 – Market Background

This section introduces readers to the historical and current scenario of the market. An assessment on the key watershed moments in the market has been outlined, to bring readers up-to-date on the current scenario.

Chapter 05 – Market Context

This section offers key information on the product USP/features, epidemiological forecast for MRSA (2014-2024). Other key points where this market touches upon are pipeline assessment, new product approvals, and clinical trial assessments. Product adoption/route of administration analysis is also covered in detail in the study

This section explains the global market value analysis and forecast for the MRSA treatment market during the forecast period. This chapter includes a detailed analysis of the historical MRSA treatment market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2020–2030).

Chapter 6 - Global MRSA Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030

This chapter gives information about COVID-19 crisis impact analysis which comprises of current COVID-19 statistics and probable future impact, impact on GDP of individual key countries, segment wise impact, quarter-wise forecast and projected recovery quarter. In addition, this chapter includes drivers and restraints of the MRSA treatment market. This section also includes macroeconomic factors and various opportunities of the MRSA treatment market.

Chapter 07 – Global MRSA Treatment Market Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

Based on drug class, MRSA treatment market is segmented into glycopeptides, lipopeptide, oxazolidinones, glycylcycline, streptogramins, lincomycin, tetracycline, lipoglycopeptides, antiseptics, naturals/herbals, and others. In this chapter, readers can find information about Y-o-Y growth and market attractiveness analysis based on drug class.

Chapter 08 – Global MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Indication

Based on indication, MRSA treatment market is segmented into skin and soft tissue infections (SSTIs), pneumonia, bloodstream infections, surgical and medical infections, and others. In this chapter, readers can understand the Y-o-Y growth and market attractiveness analysis based on indication.

Chapter 09  - Global MRSA Treatment Market Analysis 2015-2019 and Forecast 2020-2030, By Route of Administration

Based on route of administration, MRSA treatment market is segmented into intravenous, oral, topical, nasal, cutaneous, and intramuscular. In this chapter, readers can understand the Y-o-Y growth and market attractiveness analysis based on route of administration.

Chapter 10 – Global MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Types of MRSA

Based on types of MRSA, MRSA treatment market is segmented into healthcare acquired MRSA, community acquired MRSA, and hospital acquired MRSA. In this chapter, readers can understand the Y-o-Y growth and market attractiveness analysis based on types of MRSA.

Chapter 11 – Global MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Distribution Channel

Based on distribution channel, MRSA treatment market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. In this chapter, readers can understand the Y-o-Y growth and market attractiveness analysis based on distribution channel.

Chapter 12 – Global MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, by Region

This chapter explains how the MRSA treatment market will grow across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa (MEA).

Chapter 13 – North America MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030

This chapter includes a detailed analysis of growth of the North America MRSA treatment market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, and market growth based on the drug class, indication, route of administration, types of MRSA, distribution channels, and countries in North America.

Chapter 14 – Latin America MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030

This chapter provides the growth scenario of the MRSA treatment market in Latin American countries such as Brazil, Mexico, Argentina and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.

Chapter 15 – Europe MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030

Important growth prospects of the MRSA treatment market based on its distribution channels in several countries such as the U.K., France, Germany, Spain, Italy, Russia and the Rest of Europe are included in this chapter.

Chapter 16 – South Asia MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030

Important growth prospects of the MRSA treatment market based on its distribution channels in several countries such as India, Thailand, Indonesia, Malaysia and the rest of South Asia are included in this chapter.

Chapter 17 – East Asia MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030

In this chapter, China, Japan and South Korea are the prominent countries in East Asia that are the prime subjects of assessment to obtain the growth prospects of the MRSA treatment market. Readers can find detailed information about the growth parameters of the MRSA treatment market during the forecast period of 2020-2030.

Chapter 18 – Middle East & Africa (MEA) MRSA Treatment Market Analysis 2015-2019 & Opportunity Assessment 2020-2030

This chapter provides information about how the MRSA treatment market will grow in major countries in the MEA region such as GCC Countries, South Africa, and the Rest of MEA, during the forecast period of 2020-2030.

Chapter 19 – Emerging Countries MRSA Treatment Market Analysis 2015-2019 and Forecast 2020-2030

This section highlights the growth prospects of the MRSA treatment market for Australia and New Zealand, during the forecast period of 2020-2030.

Chapter 20 – Key Countries MRSA Treatment Market Analysis 2015-2019 and Forecast 2020-2030

This section analyzes the MRSA treatment in key countries around the globe, offering an analysis on the key factors and developments

Chapter 21 – Market Structure Analysis

This chapter highlights the tier structure analysis, market concentration analysis and company share analysis along with sales footprint analysis of key player operating in MRSA treatment market.

Chapter 22 – Competition Analysis

In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the MRSA treatment market, along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured are Pfizer, Inc. (U. S.), Allergan Plc. (U. S.), Johnsons & Johnson (U. S.), Merck & Co., Inc. (U. S.), Novartis AG (Switzerland), Baxter Healthcare Corporation (U. S.), Fresenius Kabi LLC (Germany), Bausch Health Companies Inc. (Canada), Cumberland Pharmaceuticals Inc. (U. S.), Melinta Therapeutics, Inc. (U. S.), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (U. S.), Dr. Reddy’s Laboratories Ltd. (India), Akron Pharma Inc. (U. S.), Mayne Pharma Group Limited. (Australia), Sun Pharmaceutical Industries Ltd. (India), Amneal Pharmaceuticals, Inc. (U. S.), Debiopharm International SA (Switzerland), Herbal Intervention, LLC (U. S.), Bio-Germ Protection LLC (U. S.), and others.

Chapter 23 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the MRSA treatment market report.

Chapter 24 – Research Methodology

This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the MRSA treatment market.

Sources and Primary Research Splits (%)

Industry Interactions

  • C - Level Executives
  • Marketing Directors
  • Product Managers
  • Business Development Officers
  • Production Managers
  • Procurement Heads
  • Sales Executives
  • Distributors
  • Traders
  • Raw Material Suppliers
  • Industry Experts
  • End Users
  • Current Market Dynamics and Challenges
  • Yesteryear Trends
  • Market Characteristics
  • Market Performance and Growth Quadrants
  • Competition Structure and Market Structure
  • Strategic Growth Initiatives
  • Near-term and Long-term Market Growth Prospects
  • Market Segment Splits and Authenticity
  • Opinions on Market Projections and Validity of Assumptions

Primary Interview Splits split by designation global methicillin resistant staphylococcus aureus testing market

References Catalogue

  • Industry Publications
    • World Health Organizations (WHO)
    • National Institute of Health (NIH)
  • Factiva
  • Company Press Releases
  • Annual Reports and Investor Presentations
  • Research Papers
  • Government Websites and Publications
  • Trade Websites

Primary Interview Splits split by stakeholders global methicillin resistant staphylococcus aureus testing market

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

Get in touch

Harish Tiwari

Global Head - Business Development

Akshay Godge

Client Partner - Global Business Development

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology